Evofem Biosciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Saundra Pelletier
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12400 High Bluff Drive San Diego CA United States of America 92130
- IPO Date
- Nov 20, 2014
- CIK
- 0001618835
- Website
- evofem.com
- Similar Companies
- Business
- Evofem Biosciences, Inc. (NASDAQ: EVFM) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health. The company offers Phexxi (lactic acid, citric acid, and potassium bitartrate), a hormone-free, on-demand prescription vaginal gel contraceptive approved by the U.S. FDA that provides non-hormonal birth control by maintaining the vaginal pH to inhibit sperm mobility; it is available through pharmacies and telehealth providers targeting women seeking alternatives to hormonal methods. Evofem also advances its pipeline of woman-centered therapies, including EVO100 for the prevention of bacterial vaginosis recurrence and other urogenital infections, and explores applications in urinary tract infections and chlamydia prevention, with clinical data demonstrating efficacy in phase 3 trials. Headquartered in San Diego, California, and founded in 2007 as a specialty pharmaceutical firm, Evofem operates primarily in the United States with distribution partnerships for Phexxi commercialization. In recent developments, the company completed a strategic financing round in 2024 to support Phexxi sales expansion and pipeline advancement following FDA approval; launched commercial-scale manufacturing enhancements for Phexxi to improve supply chain efficiency; and entered distribution alliances with telehealth platforms to broaden access amid growing demand for non-hormonal contraception. Evofem serves healthcare providers, pharmacies, and women aged 18-35 in the reproductive health segment, with ongoing efforts to expand into global markets through licensing opportunities.
Evofem Reports First Quarter 2026 Financial Results and Provides Business Update
Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa
Head-To-Head Survey: Evofem Biosciences (NASDAQ:EVFM) and Ayala Pharmaceuticals (NASDAQ:ADXS)
Evofem Reports Fifth Consecutive Year of Net Sales Growth
Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women's Health at Fierce JPM Week 2026
Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store
Financial Contrast: Evofem Biosciences (NASDAQ:EVFM) and BetterLife Pharma (OTCMKTS:PVOTF)
Evofem Biosciences (NASDAQ:EVFM) Stock Passes Above 50 Day Moving Average – What’s Next?
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE
Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey
Evofem Announces Voting Results from Special Meeting of Stockholders
Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates
Evofem Biosciences Honors World Contraception Day
Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms
Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting
Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis
Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update